Keynote Message by Dr. Samuel Zacate, Director General of the Food and Drug Administration
It is indeed an honor to address you on behalf of the Food and Drug Administration, an agency dedicated to ensuring the safety, efficacy and quality of health products mandated by the Republic Act No. 9711, otherwise known as the Food and Drug Administration Act of 2009.
In the era where advancement in science and technology are transforming the landscape of healthcare, the role of the FDA becomes more crucial.
We find ourselves at the crossroads of progress, where innovations in the pharmaceutical industry have the potential to revolutionize the way we treat, manage, and prevent diseases.
Our commitment to safeguarding public health never stops and we recognize the path forward requires a new level of collaboration and a commitment to embrace innovation.
The pharmaceutical industry is at the forefront of scientific discovery, developing cutting edge therapies, and medicine that have the power to transform lives.
The FDA aims to streamline regulatory processes requirements; ensuring that an innovative and life challenging paradox reach those in need in a timely and efficient manner. This commitment is a strategic initiative to create a regulatory environment that fosters innovation without compromising health and safety.
The FDA understands the challenges faced by the pharmaceutical industry—from the arduous journey of research and development to the rigorous regulatory scrutiny that follows.
Together, we can work towards a more efficient, transparent, and supportive regulatory system. The FDA doors are open and its commitment is unwavering.
The agency invites the pharmaceutical industry to engage in the dialogue, to share insights, and to collectively address the challenges that lies ahead.
By working hard in hand, the FDA and the pharmaceutical industry can ensure that the products entering the market meet the highest standard of safety, efficiency and quality. As the FDA commits to the journey of collaboration, it must not forget the ultimate beneficiaries of this effort are the people.
Each innovation, each breakthrough, holds the potential to alleviate suffering to improve the quality of life for countless individuals. The shared responsibility of the FDA and the pharmaceutical industry is to turn the promises of innovation into a reality for those who need it most.
In conclusion, the FDA embraces the spirit of collaboration, innovation and a shared commitment to excellence. Together, the FDA and the pharmaceutical industries can build a future where they work seamlessly to bring about a new era for medical progress.
